A certificate lets Profusa start making sensors that track oxygen in body tissue.
Profusa, Inc. (PFSA) received ISO 13485:2016 certification from GMED, a step toward MDR certification and CE marking for its Lumee Oxygen Platform. The certification covers the design, development, and manufacture of the platform at its Berkeley facility. Profusa aims to begin manufacturing the platform and pursue commercial distribution in the EU, subject to regulatory approvals.
How this was made
The 30-second read
Why it matters
The ISO 13485 certification is a prerequisite for EU market entry, signaling progress toward MDR compliance and CE marking, but revenue impact remains speculative until sales commence.
Market read
A regulatory milestone for a small‑cap med‑tech firm; may attract short‑term speculative interest but limited immediate market impact.
What to watch
Timing of CE marking and reimbursement decisions in Europe remain uncertain, which could delay revenue.
Background
Profusa is a Berkeley‑based digital health company developing injectable biosensors for continuous tissue oxygen monitoring.
Ticker impact
Profusa received ISO 13485:2016 certification, a first‑time regulatory milestone for its Lumee Oxygen platform.
likely modest upside as investors price in potential European sales
ISO 13485 is required for medical device sales in Europe; gaining it signals progress toward MDR and CE marking, but no revenue numbers are disclosed yet.
Market effects
May improve sentiment for the digital health and medical device sector as a peer clears a regulatory hurdle.
Potentially positive for European med‑tech investors awaiting new device approvals.
Limited to niche investors; no broad market effect.
Counterpoint
The certification does not guarantee MDR approval or commercial uptake; investors may wait for actual sales data.
Key entities
- CompanyProfusa, Inc.
Developer of the Lumee Oxygen tissue‑integrated biosensor platform.
- Regulatory BodyGMED
EU MDR notified body that issued the ISO 13485 certification.